Cyclo Therapeutics (CYTH) Competitors $0.71 +0.03 (+4.42%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends CYTH vs. QNCX, IMAB, CLSD, CMRX, FBLG, AVTE, EPIX, PDSB, VTGN, and ZIVOShould you be buying Cyclo Therapeutics stock or one of its competitors? The main competitors of Cyclo Therapeutics include Quince Therapeutics (QNCX), I-Mab (IMAB), Clearside Biomedical (CLSD), Chimerix (CMRX), FibroBiologics (FBLG), Aerovate Therapeutics (AVTE), ESSA Pharma (EPIX), PDS Biotechnology (PDSB), Vistagen Therapeutics (VTGN), and ZIVO Bioscience (ZIVO). These companies are all part of the "pharmaceutical products" industry. Cyclo Therapeutics vs. Quince Therapeutics I-Mab Clearside Biomedical Chimerix FibroBiologics Aerovate Therapeutics ESSA Pharma PDS Biotechnology Vistagen Therapeutics ZIVO Bioscience Quince Therapeutics (NASDAQ:QNCX) and Cyclo Therapeutics (NASDAQ:CYTH) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, dividends, community ranking, earnings, media sentiment and risk. Do institutionals & insiders hold more shares of QNCX or CYTH? 30.8% of Quince Therapeutics shares are owned by institutional investors. Comparatively, 68.6% of Cyclo Therapeutics shares are owned by institutional investors. 16.8% of Quince Therapeutics shares are owned by company insiders. Comparatively, 29.8% of Cyclo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has more risk and volatility, QNCX or CYTH? Quince Therapeutics has a beta of 0.71, indicating that its stock price is 29% less volatile than the S&P 500. Comparatively, Cyclo Therapeutics has a beta of -0.38, indicating that its stock price is 138% less volatile than the S&P 500. Does the media favor QNCX or CYTH? In the previous week, Cyclo Therapeutics had 1 more articles in the media than Quince Therapeutics. MarketBeat recorded 4 mentions for Cyclo Therapeutics and 3 mentions for Quince Therapeutics. Quince Therapeutics' average media sentiment score of 0.92 beat Cyclo Therapeutics' score of -0.08 indicating that Quince Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Quince Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cyclo Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community believe in QNCX or CYTH? Cyclo Therapeutics received 6 more outperform votes than Quince Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Quince Therapeutics an outperform vote while only 71.43% of users gave Cyclo Therapeutics an outperform vote. CompanyUnderperformOutperformQuince TherapeuticsOutperform Votes4100.00% Underperform VotesNo VotesCyclo TherapeuticsOutperform Votes1071.43% Underperform Votes428.57% Do analysts rate QNCX or CYTH? Quince Therapeutics presently has a consensus target price of $8.50, indicating a potential upside of 361.96%. Cyclo Therapeutics has a consensus target price of $0.95, indicating a potential upside of 34.03%. Given Quince Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Quince Therapeutics is more favorable than Cyclo Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Quince Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.50Cyclo Therapeutics 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33 Which has higher earnings and valuation, QNCX or CYTH? Cyclo Therapeutics has higher revenue and earnings than Quince Therapeutics. Quince Therapeutics is trading at a lower price-to-earnings ratio than Cyclo Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioQuince TherapeuticsN/AN/A-$31.39M-$1.24-1.48Cyclo Therapeutics$870.73K23.42-$20.06M-$0.90-0.79 Is QNCX or CYTH more profitable? Quince Therapeutics has a net margin of 0.00% compared to Cyclo Therapeutics' net margin of -2,847.19%. Quince Therapeutics' return on equity of -53.27% beat Cyclo Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Quince TherapeuticsN/A -53.27% -22.73% Cyclo Therapeutics -2,847.19%-2,741.89%-307.16% SummaryQuince Therapeutics beats Cyclo Therapeutics on 10 of the 18 factors compared between the two stocks. Ad Crypto Swap Profits[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.Register for the FREE Workshop Now & get $10 in Bitcoin Get Cyclo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CYTH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CYTH vs. The Competition Export to ExcelMetricCyclo TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$20.39M$2.93B$5.06B$8.82BDividend YieldN/A1.89%5.18%4.07%P/E Ratio-0.7945.61126.3117.81Price / Sales23.42360.261,178.7474.57Price / CashN/A160.0933.8632.53Price / Book3.383.734.684.68Net Income-$20.06M-$41.63M$119.54M$226.08M7 Day Performance15.31%-4.73%-1.83%-1.04%1 Month Performance-12.49%-6.53%-3.60%1.04%1 Year Performance-42.84%25.63%31.91%26.28% Cyclo Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CYTHCyclo Therapeutics2.7551 of 5 stars$0.71+4.4%$0.95+34.0%-47.9%$20.39M$870,725.00-0.799News CoverageGap UpQNCXQuince Therapeutics2.8745 of 5 stars$1.84+4.0%$8.50+362.0%+109.1%$80.96MN/A-1.4860IMABI-Mab2.5456 of 5 stars$0.98+3.2%$8.00+716.3%-37.6%$79.80M$3.89M0.0034Gap UpCLSDClearside Biomedical3.0244 of 5 stars$1.05+1.9%$5.33+407.9%+8.1%$79.63M$8.23M-2.2930Analyst RevisionCMRXChimerix4.5147 of 5 stars$0.88flat$8.50+865.9%-12.0%$79.15M$320,000.00-0.9472Analyst ForecastFBLGFibroBiologics1.729 of 5 stars$2.24-5.9%$12.00+435.7%N/A$77.64MN/A0.0010AVTEAerovate Therapeutics1.7152 of 5 stars$2.66-0.4%$2.25-15.4%-81.7%$76.81MN/A-0.8951Positive NewsEPIXESSA Pharma2.7825 of 5 stars$1.73-0.6%$11.67+574.4%-68.0%$76.76MN/A-2.8150PDSBPDS Biotechnology1.825 of 5 stars$2.03-3.3%$12.33+509.1%-67.9%$75.76MN/A-1.7520VTGNVistagen Therapeutics3.7702 of 5 stars$2.61-2.2%$15.00+474.7%-25.4%$74.34M$1.06M0.0040Positive NewsZIVOZIVO BioscienceN/A$20.96flatN/A+1,668.8%$74.33M$30,000.000.0010Negative News Related Companies and Tools Related Companies QNCX Alternatives IMAB Alternatives CLSD Alternatives CMRX Alternatives FBLG Alternatives AVTE Alternatives EPIX Alternatives PDSB Alternatives VTGN Alternatives ZIVO Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CYTH) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cyclo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cyclo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
